Priorities for developing respiratory syncytial virus vaccines in different target populations
Science Translational Medicine • 18 Mar 2020 • Vol 12, Issue 535 • DOI: 10.1126/scitranslmed.aax2466
Abstract
The development of an effective vaccine against respiratory syncytial virus (RSV) has been hampered by major difficulties that occurred in the 1960s when a formalin-inactivated vaccine led to increased severity of RSV disease after acquisition of the virus in the RSV season after vaccination. Recent renewed efforts to develop a vaccine have resulted in about 38 candidate vaccines and monoclonal antibodies now in clinical development. The target populations for effective vaccination are varied and include neonates, young children, pregnant women, and older adults. The reasons for susceptibility to infection in each of these groups may be different and, therefore, could require different vaccine types for induction of protective immune responses, adding a further challenge for vaccine development. Here, we review the current knowledge of RSV vaccine development for these target populations and propose a view and rationale for prioritizing RSV vaccine development.
Get full access to this article
View all available purchase options and get full access to this article.
Already a Subscriber?Sign In
REFERENCES AND NOTES
1
T. Shi, D. A. McAllister, K. L. O’Brien, E. A. F. Simoes, S. A. Madhi, B. D. Gessner, F. P. Polack, E. Balsells, S. Acacio, C. Aguayo, I. Alassani, A. Ali, M. Antonio, S. Awasthi, J. O. Awori, E. Azziz-Baumgartner, H. C. Baggett, V. L. Baillie, A. Balmaseda, A. Barahona, S. Basnet, Q. Bassat, W. Basualdo, G. Bigogo, L. Bont, R. F. Breiman, W. A. Brooks, S. Broor, N. Bruce, D. Bruden, P. Buchy, S. Campbell, P. Carosone-Link, M. Chadha, J. Chipeta, M. Chou, W. Clara, C. Cohen, E. de Cuellar, D. A. Dang, B. Dash-Yandag, M. Deloria-Knoll, M. Dherani, T. Eap, B. E. Ebruke, M. Echavarria, C. C. de Freitas Lázaro Emediato, R. A. Fasce, D. R. Feikin, L. Feng, A. Gentile, A. Gordon, D. Goswami, S. Goyet, M. Groome, N. Halasa, S. Hirve, N. Homaira, S. R. C. Howie, J. Jara, I. Jroundi, C. B. Kartasasmita, N. Khuri-Bulos, K. L. Kotloff, A. Krishnan, R. Libster, O. Lopez, M. G. Lucero, F. Lucion, S. P. Lupisan, D. N. Marcone, J. P. McCracken, M. Mejia, J. C. Moisi, J. M. Montgomery, D. P. Moore, C. Moraleda, J. Moyes, P. Munywoki, K. Mutyara, M. P. Nicol, D. J. Nokes, P. Nymadawa, M. T. da Costa Oliveira, H. Oshitani, N. Pandey, G. Paranhos-Baccalà, L. N. Phillips, V. S. Picot, M. Rahman, M. Rakoto-Andrianarivelo, Z. A. Rasmussen, B. A. Rath, A. Robinson, C. Romero, G. Russomando, V. Salimi, P. Sawatwong, N. Scheltema, B. Schweiger, J. A. G. Scott, P. Seidenberg, K. Shen, R. Singleton, V. Sotomayor, T. A. Strand, A. Sutanto, M. Sylla, M. D. Tapia, S. Thamthitiwat, E. D. Thomas, R. Tokarz, C. Turner, M. Venter, S. Waicharoen, J. Wang, W. Watthanaworawit, L. M. Yoshida, H. Yu, H. J. Zar, H. Campbell, H. Nair; RSV Global Epidemiology Network, Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet 390, 946–958 (2017).
2
N. Lee, G. C. Y. Lui, K. T. Wong, T. C. M. Li, E. C. M. Tse, J. Y. C. Chan, J. Yu, S. S. M. Wong, K. W. Choi, R. Y. K. Wong, K. L. K. Ngai, D. S. C. Hui, P. K. S. Chan, High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 57, 1069–1077 (2013).
3
B. Ackerson, H. F. Tseng, L. S. Sy, Z. Solano, J. Slezak, Y. Luo, C. A. Fischetti, V. Shinde, Severe morbidity and mortality associated with respiratory syncytial virus versus Influenza infection in hospitalized older adults. Clin. Infect. Dis. 69, 197–203 (2019).
4
PATH RSV vaccine snapshot, https://vaccineresources.org/files/RSV-snapshot-2019_04_05_April_High%20Resolution.pdf [accessed 15 May 2019].
5
M. C. Crank, T. J. Ruckwardt, M. Chen, K. M. Morabito, E. Phung, P. J. Costner, L. S. A. Holman, S. P. Hickman, N. M. Berkowitz, I. J. Gordon, G. V. Yamshchikov, M. R. Gaudinski, A. Kumar, L. A. Chang, S. M. Moin, J. P. Hill, A. T. DiPiazza, R. M. Schwartz, L. Kueltzo, J. W. Cooper, P. Chen, J. A. Stein, K. Carlton, J. G. Gall, M. C. Nason, P. D. Kwong, G. L. Chen, J. R. Mascola, J. S. McLellan, J. E. Ledgerwood, B. S. Graham; VRC 317 Study Team, A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505–509 (2019).
6
J. Murray, A. Bottle, M. Sharland, N. Modi, P. Aylin, A. Majeed, S. Saxena; Medicines for Neonates Investigator Group, Risk factors for hospital admission with RSV bronchiolitis in England: A population-based birth cohort study. PLOS ONE 9, e89186 (2014).
7
C. A. Thornton, J. W. Upham, M. E. Wikström, B. J. Holt, G. P. White, M. J. Sharp, P. D. Sly, P. G. Holt, Functional maturation of CD4+CD25+CTLA4+CD45RA+ T regulatory cells in human neonatal T cell responses to environmental antigens/allergens. J. Immunol. 173, 3084–3092 (2004).
8
R. Ochola, C. Sande, G. Fegan, P. D. Scott, G. F. Medley, P. A. Cane, D. J. Nokes, The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLOS ONE 4, e8088 (2009).
9
J. E. Crowe Jr., Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin. Infect. Dis. 33, 1720–1727 (2001).
10
J. Moyes, C. Cohen, M. Pretorius, M. Groome, A. von Gottberg, N. Wolter, S. Walaza, S. Haffejee, M. Chhagan, F. Naby, A. L. Cohen, S. Tempia, K. Kahn, H. Dawood, M. Venter, S. A. Madhi; South African Severe Acute Respiratory Illness Surveillance Group, Epidemiology of respiratory syncytial virus–associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010–2011. J. Infect. Dis. 208, S217–S226 (2013).
11
A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, E. E. Walsh, Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749–1759 (2005).
12
F. W. Henderson, A. M. Collier, W. A. Clyde Jr., F. W. Denny, Respiratory-syncytial-virus infections, reinfections and immunity—A prospective, longitudinal study in young children. N. Engl. J. Med. 300, 530–534 (1979).
13
C. B. Hall, E. E. Walsh, C. E. Long, K. C. Schnabel, Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693–698 (1991).
14
H. W. Kim, J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, R. H. Parrott, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
15
J. E. Salk, Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J. Am. Med. Assoc. 151, 1081–1098 (1953).
16
P. M. Strebel, R. W. Sutter, S. L. Cochi, R. J. Biellik, E. W. Brink, O. M. Kew, M. A. Pallansch, W. A. Orenstein, A. R. Hinman, Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14, 568–579 (1992).
17
L. Potash, A. A. Tytell, B. H. Sweet, R. A. Machlowitz, J. Stokes Jr., R. E. Weibel, A. F. Woodhour, M. R. Hilleman, Respiratory virus vaccines. I. Respiratory syncytial and parainfluenza virus vaccines. Am. Rev. Respir. Dis. 93, 536–548 (1966).
18
J. Chin, R. L. Magoffin, L. A. Shearer, Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89, 449–463 (1969).
19
R. E. Weibel, J. Stokes Jr., M. B. Leagus, C. C. Mascoli, A. A. Tytell, A. F. Woodhour, P. P. Vella, M. R. Hilleman, Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966. Am. Rev. Respir. Dis. 96, 724–739 (1967).
20
R. E. Weibel, J. Stokes Jr., M. B. Leagus, C. C. Mascoli, M. R. Hilleman, Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am. Rev. Respir. Dis. 94, 362–379 (1966).
21
G. Taylor, Animal models of respiratory syncytial virus infection. Vaccine 35, 469–480 (2017).
22
B. R. Murphy, G. A. Prince, E. E. Walsh, H. W. Kim, R. H. Parrott, V. G. Hemming, W. J. Rodriguez, R. M. Chanock, Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24, 197–202 (1986).
23
B. R. Murphy, E. E. Walsh, Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26, 1595–1597 (1988).
24
M. F. Delgado, S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H.-Y. Chang, W. Mitzner, J. Ravetch, J. A. Melero, P. M. Irusta, F. P. Polack, Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34–41 (2009).
25
C. A. Shaw, G. Otten, A. Wack, G. A. Palmer, C. W. Mandl, M. L. Mbow, N. Valiante, P. R. Dormitzer, Antibody affinity maturation and respiratory syncytial virus disease. Nat. Med. 15, 725 (2009).
26
A. Moghaddam, W. Olszewska, B. Wang, J. S. Tregoning, R. Helson, Q. J. Sattentau, P. J. M. Openshaw, A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12, 905–907 (2006).
27
A. M. Killikelly, M. Kanekiyo, B. S. Graham, Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci. Rep. 6, 34108 (2016).
28
European Medicines Agency, Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of respiratory syncytial virus (RSV) disease, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-indicated-prophylaxis-treatment-respiratory_en.pdf [accessed 15 May 2019].
29
M. Connors, P. L. Collins, C.-Y. Firestone, A. V. Sotnikov, A. Waitze, A. R. Davis, P. P. Hung, R. M. Chanock, B. R. Murphy, Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSV. Vaccine 10, 475–484 (1992).
30
M. E. Waris, C. Tsou, D. D. Erdman, S. R. Zaki, L. J. Anderson, Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70, 2852–2860 (1996).
31
C. S. Ambrose, X. Wu, R. B. Belshe, The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr. Infect. Dis. J. 29, 806–811 (2010).
32
E. E. Walsh, A. R. Falsey, Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis. 190, 373–378 (2004).
33
R. A. Karron, U. J. Buchholz, P. L. Collins, Live-attenuated respiratory syncytial virus vaccines. Curr. Top. Microbiol. Immunol. 372, 259–284 (2013).
34
C. A. Rostad, C. C. Stobart, B. E. Gilbert, R. J. Pickles, A. L. Hotard, J. Meng, J. C. G. Blanco, S. M. Moin, B. S. Graham, P. A. Piedra, M. L. Moore, A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein Is immunogenic and protective against challenge in cotton rats. J. Virol. 90, 7508–7518 (2016).
35
R. A. Karron, P. F. Wright, J. E. Crowe Jr., M. L. Clements-Mann, J. Thompson, M. Makhene, R. Casey, B. R. Murphy, Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176, 1428–1436 (1997).
36
T. Dudek, D. M. Knipe, Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230–239 (2006).
37
Z. Xing, B. D. Lichty, Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis 86, 211–217 (2006).
38
K. J. Ewer, K. Sierra-Davidson, A. M. Salman, J. J. Illingworth, S. J. Draper, S. Biswas, A. V. S. Hill, Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity”. Vaccine 33, 7444–7451 (2015).
39
C. A. Green, E. Scarselli, C. J. Sande, A. J. Thompson, C. M. de Lara, K. S. Taylor, K. Haworth, M. Del Sorbo, B. Angus, L. Siani, S. Di Marco, C. Traboni, A. Folgori, S. Colloca, S. Capone, A. Vitelli, R. Cortese, P. Klenerman, A. Nicosia, A. J. Pollard, Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med. 7, 300ra126 (2015).
40
R. A. Tripp, S. M. Tompkins, Virus-vectored influenza virus vaccines. Viruses 6, 3055–3079 (2014).
41
M. O. Afolabi, A. B. Tiono, U. J. Adetifa, J. B. Yaro, A. Drammeh, I. Nébié, C. Bliss, S. H. Hodgson, N. A. Anagnostou, G. S. Sanou, Y. J. Jagne, O. Ouedraogo, C. Tamara, N. Ouedraogo, M. Ouedraogo, J. Njie-Jobe, A. Diarra, C. J. A. Duncan, R. Cortese, A. Nicosia, R. Roberts, N. K. Viebig, O. Leroy, A. M. Lawrie, K. L. Flanagan, B. Kampman, P. Bejon, E. B. Imoukhuede, K. J. Ewer, A. V. S. Hill, K. Bojang, S. B. Sirima, Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol. Ther. 24, 1470–1477 (2016).
42
K. J. Ewer, T. Lambe, C. S. Rollier, A. J. Spencer, A. V. S. Hill, L. Dorrell, Viral vectors as vaccine platforms: From immunogenicity to impact. Curr. Opin. Immunol. 41, 47–54 (2016).
43
IMpact-RSV Study Group, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537 (1998).
44
Public Health England. Immunisation against infectious disease (2015): Green Book, Chapter 27a Respiratory syncytial virus, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/458469/Green_Book_Chapter_27a_v2_0W.PDF [accessed 15 May 2019].
45
X. Carbonell-Estrany, E. A. F. Simões, R. Dagan, C. B. Hall, B. Harris, M. Hultquist, E. M. Connor, G. A. Losonsky; Motavizumab Study Group, Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial. Pediatrics 125, e35–e51 (2010).
46
AstraZeneca withdraws BLA for motavizumab for serious respiratory syncytial virus (RSV) – MPR, https://www.empr.com/home/news/drugs-in-the-pipeline/astrazeneca-withdraws-bla-for-motavizumab-for-serious-respiratory-syncytial-virus-rsv/ [accessed 5 March 2019).
47
Regeneron Pharmaceuticals I. Regeneron to discontinue development of Suptavumab for Respiratory Syncytial Virus—Regeneron Pharmaceuticals Inc. 2017, https://investor.regeneron.com/news-releases/news-release-details/regeneron-discontinue-development-suptavumab-respiratory?releaseid=1037184 [accessed 4 January 2019].
48
J. B. Domachowske, A. A. Khan, M. T. Esser, K. Jensen, T. Takas, T. Villafana, F. Dubovsky, M. P. Griffin, Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr. Infect. Dis. J. 37, 886–892 (2018).
49
ClinicalTrials.gov, Safety, tolerability, and pharmacokinetics of MK-1654 in infants (MK-1654-002), https://clinicaltrials.gov/ct2/show/NCT03524118?term=merck&cond=RSV+Infection&rank=1 [accessed 5 March 2019].
50
Q. Zhu, J. S. McLellan, N. L. Kallewaard, N. D. Ulbrandt, S. Palaszynski, J. Zhang, B. Moldt, A. Khan, C. Svabek, J. M. McAuliffe, D. Wrapp, N. K. Patel, K. E. Cook, B. W. M. Richter, P. C. Ryan, A. Q. Yuan, J. A. Suzich, A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci. Transl. Med. 9, eaaj1928 (2017).
51
Q. Zhu, B. Lu, P. McTamney, S. Palaszynski, S. Diallo, K. Ren, N. D. Ulbrandt, N. Kallewaard, W. Wang, F. Fernandes, S. Wong, C. Svabek, B. Moldt, M. T. Esser, H. Jing, J. A. A. Suzich, Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897. J. Infect. Dis. 218, 572–580 (2018).
52
C. J. Sande, P. A. Cane, D. J. Nokes, The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine 32, 4726–4729 (2014).
53
S. Hashira, S. Okitsu-Negishi, K. Yoshino, Placental transfer of IgG subclasses in a Japanese population. Pediatr. Int. 42, 337–342 (2000).
54
L. Liu, S. Oza, D. Hogan, J. Perin, I. Rudan, J. E. Lawn, S. Cousens, C. Mathers, R. E. Black, Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: An updated systematic analysis. Lancet 385, 430–440 (2015).
55
G. M. Glenn, L. F. Fries, D. N. Thomas, G. Smith, E. Kpamegan, H. Lu, D. Flyer, D. Jani, S. P. Hickman, P. A. Piedra, A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J. Infect. Dis. 213, 411–422 (2016).
56
M. F. MacDorman, E. C. W. Gregory, Fetal and perinatal mortality: United States, 2013. Natl. Vital Stat. Rep. 64, 1–24 (2015).
57
World Health Organization, World Health Statistics: 2013, https://who.int/gho/publications/world_health_statistics/EN_WHS2013_Full.pdf [accessed 19 February 2019].
58
R. Raghunandan, H. Lu, B. Zhou, M. G. Xabier, M. J. Massare, D. C. Flyer, L. F. Fries, G. E. Smith, G. M. Glenn, An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 32, 6485–6492 (2014).
59
Novavax announces topline results from Phase 3 PrepareTM trial of ResVaxTM for prevention of RSV disease in infants via maternal immunization—Novavax Inc.—IR Site, http://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial [accessed 5 March 2019].
60
P. Palmeira, C. Quinello, A. L. Silveira-Lessa, C. A. Zago, M. Carneiro-Sampaio, IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012, 985646 (2012).
61
J. E. Atwell, B. Thumar, L. J. Robinson, R. Tobby, P. Yambo, M. Ome-Kaius, P. M. Siba, H. W. Unger, S. J. Rogerson, C. L. King, R. A. Karron, Impact of placental malaria and bol on transplacental transfer of respiratory syncytial virus antibody in Papua New Guinea. J. Infect. Dis. 213, 423–431 (2016).
62
A. B. Hogan, P. T. Campbell, C. C. Blyth, F. J. Lim, P. Fathima, S. Davis, H. C. Moore, K. Glass, Potential impact of a maternal vaccine for RSV: A mathematical modelling study. Vaccine 35, 6172–6179 (2017).
63
J. U. Nyiro, I. K. Kombe, C. J. Sande, J. Kipkoech, P. K. Kiyuka, C. O. Onyango, P. K. Munywoki, T. M. Kinyanjui, D. J. Nokes, Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya. PLOS ONE 12, e0177803 (2017).
64
D. Cromer, A. J. van Hoek, A. T. Newall, M. Jit, Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: A modelling and cost-effectiveness analysis for England. Lancet Public Health 2, e367–e374 (2017).
65
S. Janet, J. Broad, M. D. Snape, Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum. Vaccin. Immunother. 14, 234–244 (2018).
66
S. Taylor, R. J. Taylor, R. L. Lustig, C. Schuck-Paim, F. Haguinet, D. J. Webb, J. Logie, G. Matias, D. M. Fleming, Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. BMJ Open 6, e009337 (2016).
67
T. Jefferson, A. Rivetti, C. Di Pietrantonj, V. Demicheli, Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2, CD004879 (2018).
68
J. P. Mullooly, C. B. Bridges, W. W. Thompson, J. Chen, E. Weintraub, L. A. Jackson, S. Black, D. K. Shay; Vaccine Safety Datalink Adult Working Group, Influenza- and RSV-associated hospitalizations among adults. Vaccine 25, 846–855 (2007).
69
A. G. S. C. Jansen, E. A. M. Sanders, A. W. Hoes, A. M. van Loon, E. Hak, Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur. Respir. J. 30, 1158–1166 (2007).
70
H. Zhou, W. W. Thompson, C. G. Viboud, C. M. Ringholz, P. Y. Cheng, C. Steiner, G. R. Abedi, L. J. Anderson, L. Brammer, D. K. Shay, Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. Clin. Infect. Dis. 54, 1427–1436 (2012).
71
L. van Asten, C. van den Wijngaard, W. van Pelt, J. van de Kassteele, A. Meijer, W. van der Hoek, M. Kretzschmar, M. Koopmans, Mortality attributable to 9 common infections: Significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J. Infect. Dis. 206, 628–639 (2012).
72
W. W. Thompson, D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson, K. Fukuda, Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179–186 (2003).
73
C. Volling, K. Hassan, T. Mazzulli, K. Green, A. Al-den, P. Hunter, R. Mangat, J. Ng, A. McGeer, Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect. Dis. 14, 665 (2014).
74
K. Widmer, Y. Zhu, J. V. Williams, M. R. Griffin, K. M. Edwards, H. K. Talbot, Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J. Infect. Dis. 206, 56–62 (2012).
75
S. F. Dowell, L. J. Anderson, H. E. Gary, D. D. Erdman, J. F. Plouffe, T. M. File Jr., B. J. Marston, R. F. Breiman, Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174, 456–462 (1996).
76
P. J. M. Openshaw, C. Chiu, F. J. Culley, C. Johansson, Protective and harmful immunity to RSV infection. Annu. Rev. Immunol. 35, 501–532 (2017).
77
E. E. Walsh, A. R. Falsey, Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol. 73, 295–299 (2004).
78
A. Cherukuri, K. Patton, R. A. Gasser Jr., F. Zuo, J. Woo, M. T. Esser, R. S. Tang, Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin. Vaccine Immunol. 20, 239–247 (2013).
79
Novavax. Novavax announces topline RSV F vaccine data from two clinical trials in older adults—Novavax Inc.—IR Site. 2016, http://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-rsv-f-vaccine-data-two-clinical-trials [accessed 5 January 2019].
80
J. Marcandalli, B. Fiala, S. Ols, M. Perotti, W. de van der Schueren, J. Snijder, E. Hodge, M. Benhaim, R. Ravichandran, L. Carter, W. Sheffler, L. Brunner, M. Lawrenz, P. Dubois, A. Lanzavecchia, F. Sallusto, K. K. Lee, D. Veesler, C. E. Correnti, L. J. Stewart, D. Baker, K. Loré, L. Perez, N. P. King, Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420–1431.e17 (2019).
81
G. M. Glenn, G. Smith, L. Fries, R. Raghunandan, H. Lu, B. Zhou, D. N. Thomas, S. P. Hickman, E. Kpamegan, S. Boddapati, P. A. Piedra, Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31, 524–532 (2013).
82
M. Connors, N. A. Giese, A. B. Kulkarni, C. Y. Firestone, H. C. Morse III, B. R. Murphy, Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68, 5321–5325 (1994).
83
B. R. Murphy, A. V. Sotnikov, L. A. Lawrence, S. M. Banks, G. A. Prince, Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine 8, 497–502 (1990).
84
R. A. Bem, J. B. Domachowske, H. F. Rosenberg, Animal models of human respiratory syncytial virus disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L148–L156 (2011).
85
G. A. Prince, R. L. Horswood, J. Berndt, S. C. Suffin, R. M. Chanock, Respiratory syncytial virus infection in inbred mice. Infect. Immun. 26, 764–766 (1979).
86
W. H. Alwan, W. J. Kozlowska, P. J. M. Openshaw, Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179, 81–89 (1994).
87
T. Hussell, A. Georgiou, T. Sparer, S. Matthews, P. Pala, P. J. Openshaw, Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J. Immunol. 161, 6215–6222 (1998).
88
T. R. Johnson, M. N. Teng, P. L. Collins, B. S. Graham, Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78, 6024–6032 (2004).
89
A. R. Falsey, E. E. Walsh, J. Capellan, S. Gravenstein, M. Zambon, E. Yau, G. J. Gorse, R. Edelman, F. G. Hayden, J. E. McElhaney, K. M. Neuzil, K. L. Nichol, E. A. F. Simões, P. F. Wright, V. M. P. Sales, Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—Nonadjuvanted vaccine or vaccine adjuvanted with alum—Given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 198, 1317–1326 (2008).
90
J. M. Langley, V. Sales, A. McGeer, R. Guasparini, G. Predy, W. Meekison, M. Li, J. Capellan, E. Wang, A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine 27, 5913–5919 (2009).
91
U. F. Power, T. N. Nguyen, E. Rietveld, R. L. de Swart, J. Groen, A. D. M. E. Osterhaus, R. de Groot, N. Corvaia, A. Beck, N. Bouveret-le-Cam, J.-Y. Bonnefoy, Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184, 1456–1460 (2001).
92
Y. Murata, Respiratory syncytial virus vaccine development. Clin. Lab. Med. 29, 725–739 (2009).
93
R. A. Karron, C. Luongo, B. Thumar, K. M. Loehr, J. A. Englund, P. L. Collins, U. J. Buchholz, A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci. Transl. Med. 7, 312ra175 (2015).
94
R. A. Karron, P. F. Wright, R. B. Belshe, B. Thumar, R. Casey, F. Newman, F. P. Polack, V. B. Randolph, A. Deatly, J. Hackell, W. Gruber, B. R. Murphy, P. L. Collins, Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093–1104 (2005).
95
P. F. Wright, R. B. Belshe, H. W. Kim, L. P. Van Voris, R. M. Chanock, Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun. 37, 397–400 (1982).
96
E. Malkin, R. Yogev, N. Abughali, J. Sliman, C. K. Wang, F. Zuo, C. F. Yang, M. Eickhoff, M. T. Esser, R. S. Tang, F. Dubovsky, Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLOS ONE 8, e77104 (2013).
97
D. I. Bernstein, E. Malkin, N. Abughali, J. Falloon, T. Yi, F. Dubovsky; MI-CP149 Investigators, Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr. Infect. Dis. J. 31, 109–114 (2012).
98
M. Gomez, M. A. Mufson, F. Dubovsky, C. Knightly, W. Zeng, G. Losonsky, Phase-I study medi-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr. Infect. Dis. J. 28, 655–658 (2009).
99
R. S. Tang, R. R. Spaete, M. W. Thompson, M. MacPhail, J. M. Guzzetta, P. C. Ryan, K. Reisinger, P. Chandler, M. Hilty, R. E. Walker, M. M. Gomez, G. A. Losonsky, Development of a PIV-vectored RSV vaccine: Preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26, 6373–6382 (2008).
100
P. J. Watt, B. S. Robinson, C. R. Pringle, D. A. J. Tyrrel, Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8, 231–236 (1990).
101
C. R. Pringle, A. H. Filipiuk, B. S. Robinson, P. J. Watt, P. Higgins, D. A. J. Tyrrell, Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11, 473–478 (1993).
102
R. A. Karron, D. A. Buonagurio, A. F. Georgiu, S. S. Whitehead, J. E. Adamus, M. L. Clements-Mann, D. O. Harris, V. B. Randolph, S. A. Udem, B. R. Murphy, M. S. Sidhu, Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. U.S.A. 94, 13961–13966 (1997).
103
P. F. Wright, R. A. Karron, S. A. Madhi, J. J. Treanor, J. C. King, A. O’Shea, M. R. Ikizler, Y. Zhu, P. L. Collins, C. Cutland, V. B. Randolph, A. M. Deatly, J. G. Hackell, W. C. Gruber, B. R. Murphy, The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis. 193, 573–581 (2006).
104
W. T. Friedewald, B. R. Forsyth, C. B. Smith, M. A. Gharpure, R. M. Chanock, Low-temperature-grown RS virus in adult volunteers. JAMA 204, 690–694 (1968).
105
H. W. Kim, J. O. Arrobio, G. Pyles, C. D. Brandt, E. Camargo, R. M. Chanock, R. H. Parrott, Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48, 745–755 (1971).
106
P. F. Wright, V. Mills, R. M. J. Chanock, Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J. Infect. Dis. 124, 505–511 (1971).
107
H. W. Kim, J. O. Arrobio, C. D. Brandt, P. Wright, D. Hodes, R. M. Chanock, R. H. Parrott, Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52, 56–63 (1973).
108
P. F. Wright, T. Shinozaki, W. Fleet, S. H. Sell, J. Thompson, D. T. Karzon, Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88, 931–936 (1976).
109
P. F. Wright, R. A. Karron, R. B. Belshe, J. Thompson, J. E. Crowe Jr., T. G. Boyce, L. L. Halburnt, G. W. Reed, S. S. Whitehead, E. L. Anderson, A. E. Wittek, R. Casey, M. Eichelberger, B. Thumar, V. B. Randolph, S. A. Udem, R. M. Chanock, B. R. Murphy, Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182, 1331–1342 (2000).
110
I. M. Gonzalez, R. A. Karron, M. Eichelberger, E. E. Walsh, V. W. Delagarza, R. Bennett, R. M. Chanock, B. R. Murphy, M. L. Clements-Mann, A. R. Falsey, Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18, 1763–1772 (2000).
111
R. B. Belshe, E. L. Anderson, E. E. Walsh, Immunogenicity of purified F glycoprotein of respiratory syncytial virus: Clinical and immune responses to subsequent natural infection in children. J. Infect. Dis. 168, 1024–1029 (1993).
112
P. R. Paradiso, S. W. Hildreth, D. A. Hogerman, D. J. Speelman, E. B. Lewin, J. Oren, D. H. Smith, Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr. Infect. Dis. J. 13, 792–798 (1994).
113
P. A. Piedra, W. P. Glezen, J. A. Kasel, R. C. Welliver, A. M. Jewel, Y. Rayford, D. A. Hogerman, S. W. Hildreth, P. R. Paradiso, Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): The Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 13, 1095–1101 (1995).
114
D. A. Tristram, R. C. Welliver, D. A. Hogerman, S. W. Hildreth, P. Paradiso, Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: Evaluation of antibody persistence and possible disease enhancement. Vaccine 12, 551–556 (1994).
115
D. A. Tristram, R. C. Welliver, C. K. Mohar, D. A. Hogerman, S. W. Hildreth, P. Paradiso, Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167, 191–195 (1993).
116
E. E. Walsh, C. B. Hall, J. J. Schlesinger, M. W. Brandriss, S. Hildreth, P. Paradiso, Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J. Gen. Virol. 70, 2953–2961 (1989).
117
F. M. Muñoz, P. A. Piedra, W. P. Glezen, Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21, 3465–3467 (2003).
118
A. R. Falsey, E. E. Walsh, Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14, 1214–1218 (1996).
119
A. R. Falsey, E. E. Walsh, Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15, 1130–1132 (1997).
120
J. R. Groothuis, S. J. King, D. A. Hogerman, P. R. Paradiso, E. A. F. Simoes, Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177, 467–469 (1998).
121
R. C. Welliver, D. A. Tristram, K. Batt, M. Sun, D. Hogerman, S. Hildreth, Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J. Infect. Dis. 170, 425–428 (1994).
122
P. A. Piedra, S. G. Cron, A. Jewell, N. Hamblett, R. McBride, M. A. Palacio, R. Ginsberg, C. M. Oermann, P. W. Hiatt, Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: A multi-center trial in children with cystic fibrosis. Vaccine 21, 2448–2460 (2003).
123
J. Falloon, J. Yu, M. T. Esser, T. Villafana, L. Yu, F. Dubovsky, T. Takas, M. J. Levin, A. R. Falsey, An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J. Infect. Dis. 216, 1362–1370 (2017).
124
A. August, G. M. Glenn, E. Kpamegan, S. P. Hickman, D. Jani, H. Lu, D. N. Thomas, J. Wen, P. A. Piedra, L. F. Fries, A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine 35, 3749–3759 (2017).
125
L. Fries, V. Shinde, J. J. Stoddard, D. N. Thomas, E. Kpamegan, H. Lu, G. Smith, S. P. Hickman, P. Piedra, G. M. Glenn, Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun. Ageing 14, 8 (2017).
126
J. M. Langley, N. Aggarwal, A. Toma, S. A. Halperin, S. A. McNeil, L. Fissette, W. Dewé, M. Leyssen, J. F. Toussaint, I. Dieussaert, A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J. Infect. Dis. 215, 24–33 (2017).
127
J. Falloon, F. Ji, C. Curtis, S. Bart, E. Sheldon, D. Krieger, F. Dubovsky, S. Lambert, T. Takas, T. Villafana, M. T. Esser, A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 34, 2847–2854 (2016).
128
J. M. Langley, L. D. MacDonald, G. M. Weir, D. MacKinnon-Cameron, L. Ye, S. McNeil, B. Schepens, X. Saelens, M. M. Stanford, S. A. Halperin, A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: A first-in-humans study. J. Infect. Dis. 218, 378–387 (2018).
129
U. J. Buchholz, C. K. Cunningham, P. Muresan, D. Gnanashanmugam, P. Sato, G. K. Siberry, V. Rexroad, M. Valentine, C. Perlowski, E. Schappell, B. Thumar, C. Luongo, E. Barr, M. Aziz, R. Yogev, S. A. Spector, P. L. Collins, E. J. McFarland, R. A. Karron; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 Study Team, Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J. Infect. Dis. 217, 1338–1346 (2018).
130
E. J. McFarland, R. A. Karron, P. Muresan, C. K. Cunningham, M. E. Valentine, C. Perlowski, B. Thumar, D. Gnanashanmugam, G. K. Siberry, E. Schappell, E. Barr, V. Rexroad, R. Yogev, S. A. Spector, M. Aziz, N. Patel, M. Cielo, C. Luongo, P. L. Collins, U. J. Buchholz; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2000 Study Team, Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children. J. Infect. Dis. 217, 1347–1355 (2018).
131
J. Beran, J. D. Lickliter, T. F. Schwarz, C. Johnson, L. Chu, J. B. Domachowske, P. van Damme, K. Withanage, L. A. Fissette, M. P. David, K. Maleux, A. C. Schmidt, M. Picciolato, I. Dieussaert, Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: Results from 2 phase 2 trials. J. Infect. Dis. 217, 1616–1625 (2018).
132
H. H. Nam, M. G. Ison, Respiratory syncytial virus infection in adults. BMJ 366, l5021 (2019).
Information & Authors
Information
Published In
Science Translational Medicine
Volume 12 | Issue 535
March 2020
March 2020
Copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
This is an article distributed under the terms of the Science Journals Default License.
Submission history
Received: 7 March 2019
Accepted: 25 September 2019
Acknowledgments
Funding: We were supported by the NIHR Oxford Biomedical Research Centre. S.B.D., A.J.P., and C.J.S. are members of the REspiratory Syncytial virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116019. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). C.J.S. is supported by fellowship funding from the Wellcome Trust (WT105882MA). Competing interests: A.J.P. chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation (JCVI) and the European Medicines Agency Scientific Advisory Group on Vaccines and is a member of the World Health Organization’s Strategic Group of Experts. The views expressed in this manuscript do not necessarily reflect the views of these agencies. A.J.P. and C.S.R. are Jenner Institute investigators. S.B.D. has been an investigator on studies funded by Janssen and MedImmune; all funds have been paid to S.B.D.’s institution, and S.B.D. has received no personal payments. The other authors declare that they have no competing interests.
Authors
Funding Information
European Commission: RESCEU
NIHR Oxford Biomedical Research Centre
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Implementation strategies for passive respiratory syncytial virus immunisation, The Lancet Infectious Diseases, (2021).https://doi.org/10.1016/S1473-3099(20)30717-9
- Socioeconomic costs of children <5 years hospitalised with acute respiratory infections in Kuala Lumpur, Malaysia, Vaccine, 39, 22, (2983-2988), (2021).https://doi.org/10.1016/j.vaccine.2021.04.010
- Aging and Options to Halt Declining Immunity to Virus Infections, Frontiers in Immunology, 12, (2021).https://doi.org/10.3389/fimmu.2021.681449
- Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting, BMC Medicine, 18, 1, (2020).https://doi.org/10.1186/s12916-020-01783-8
- The Application of Single-Cell RNA Sequencing in Vaccinology, Journal of Immunology Research, 2020, (1-19), (2020).https://doi.org/10.1155/2020/8624963
- Innate and adaptive immune responses in respiratory virus infection: implications for the clinic, Expert Review of Respiratory Medicine, 14, 11, (1141-1147), (2020).https://doi.org/10.1080/17476348.2020.1807945
- SETTING THE PRIORITIES RIGHT IN THE COVID-19 PANDEMIC, Qeios, (2020).https://doi.org/10.32388/TSL2KJ
- SETTING THE PRIORITIES RIGHT IN THE COVID-19 PANDEMIC, Qeios, (2020).https://doi.org/10.32388/TSL2KJ.2
Loading...
View Options
Get Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Register for free to read this article
As a service to the community, this article is available for free. Login or register for free to read this article.
View options
PDF format
Download this article as a PDF file
Download PDF